Advance patient outcomes using Comprehensive Genomic Profiling

Gain therapy selection insights using the PanTracer Portfolio

Precision oncology: Liquid and tissue CGP testing solutions for oncologists

The PanTracer portfolio delivers on an ongoing NeoGenomics promise to develop tests that are practical, powerful, and designed to support real-world clinical decisions. See what makes the PanTracer Portfolio uniquely powerful.

PanTracer Tissue and PanTracer LBx are comprehensive genomic profiling (CGP) tests for patients with advanced-stage solid tumors. This portfolio of tests empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.

Download the Brochure

PanTracer strengthens treatment decisions and guides therapy selection with three powerful product options

microscope

PanTracer Tissue

A tissue-based CGP approach, providing deep insights into tumor genomics from solid-tumor biopsy samples.

Order now

hands

PanTracer Tissue + HRD

A tissue-based CGP approach with integrated HRD assessment delivers real-time molecular insights for informed and effective treatment strategies for ovarian cancer.

Order now

molecule

PanTracer LBx

A liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw to deliver real-time decision-making.

Order now

 

Download the Brochure

Powerful, simple solutions for therapy-selection

PanTracer Tissue and PanTracer LBx work together seamlessly to maximize genomic insights. Order these tests independently or as complementary tests based on your patient’s unique needs. When every answer counts, PanTracer is there to support you.

 

PanTracer Features

Broad CGP panel covering >500 genes: Detection from DNA and RNA sequencing for PanTracer Tissue, and circulating tumor DNA (ctDNA) sequencing for PanTracer LBx

Results in 8-10 days for PanTracer Tissue and PanTracer Tissue + HRD, and within 7 days for PanTracer LBx

Clear, concise reports to support rapid clinical decisions including approved targeted therapies and clinical trial opportunities based on real-time genomic data

Broad content covering over 500 biomarkers, detecting both guideline-recommended and emerging alterations.

 

Download the Brochure

Get to know the PanTracer suite of products

PanTracer Tissue

In oncology, every decision matters. PanTracer Tissue offers broad, tissue-based CGP designed to support oncologists in delivering personalized care. Aligned with clinical guidelines, this test covers key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment.

  • Analyzes over 500 genes from DNA and RNA, detecting SNVs, InDels, CNVs, and fusions to provide deep molecular insights
  • Rapid turnaround time to support timely treatment decisions with results available within 8-10 days
  • Minimal specimen requirements supporting broader patient access

 

Order now

PanTracer Tissue + HRD

Our advanced HRD score assesses BRCA1/2 and tumor genomic instability score (GIS), including LOH, TAI, and LST, to guide personalized treatment decisions.

  • Supports timely decision making
  • Results available within 8-10 days  
  • Obtain critical genomic insights from a single sample

 

Order now

PanTracer LBx

In the evolving landscape of precision oncology, accessing tumor-specific genomic insights quickly and noninvasively is critical. PanTracer LBx is a liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw. It empowers real-time decision-making, especially for patients for whom tissue biopsies are not feasible.

  • 514-gene panel covering all major variant classes from ctDNA sequencing  
  • High sensitivity, ctDNA sequencing for detection from blood samples
  • Minimally invasive CGP results, ideal for patients where tissue testing fails or when tissue is unavailable

 

Order now

PanTracer Tissue

In oncology, every decision matters. PanTracer Tissue offers broad, tissue-based CGP designed to support oncologists in delivering personalized care. Aligned with clinical guidelines, this test covers key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment.

  • Analyzes over 500 genes from DNA and RNA, detecting SNVs, InDels, CNVs, and fusions to provide deep molecular insights
  • Rapid turnaround time to support timely treatment decisions with results available within 8-10 days
  • Minimal specimen requirements supporting broader patient access

 

Order now

PanTracer Tissue + HRD

Our advanced HRD score assesses BRCA1/2 and tumor genomic instability score (GIS), including LOH, TAI, and LST, to guide personalized treatment decisions.

  • Supports timely decision making
  • Results available within 8-10 days  
  • Obtain critical genomic insights from a single sample

 

Order now

PanTracer LBx

In the evolving landscape of precision oncology, accessing tumor-specific genomic insights quickly and noninvasively is critical. PanTracer LBx is a liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw. It empowers real-time decision-making, especially for patients for whom tissue biopsies are not feasible.

  • 514-gene panel covering all major variant classes from ctDNA sequencing  
  • High sensitivity, ctDNA sequencing for detection from blood samples
  • Minimally invasive CGP results, ideal for patients where tissue testing fails or when tissue is unavailable

 

Order now

 

Download the Brochure